Notícias

Hims & Hers drops after posting unexpected quarterly loss

Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.

HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.

Hims & Hers (NYSE:HIMS) reported first quarter financial results that included a wider-than-expected loss and softer revenue performance, sending shares down nearly 14% to about $25 on Tuesday morning. For the quarter, the telehealth company posted a net loss of $92.1 million, or $0.40...

Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target to $33 from $35 while reaffirming an Overweight rating, characterizing results as mixed and updating the 2026 outlook to reflect the strategic shift ... JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story

Hims & Hers slashed its profitability outlook for 2026. The news sent Hims stock into free fall Tuesday morning.

Hims & Hers missed on both the top and bottom line

Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.

Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.

By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -519.58% and -1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Hims & Hers missed first-quarter earnings estimates, posting a loss as weakness in its American operations offset gains overseas.

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $690 million at the midpoint, or 6% above analysts’ estimates. Its GAAP loss of $0.40 per share was significantly below analysts’ consensus estimates.

Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Two class action lawsuits claim Hims & Hers Health did not adequately safeguard sensitive customer data during recent data breaches. The suits allege delayed notification to affected customers and increased risk of identity theft, and they seek damages plus stronger data security oversight. These cases introduce fresh legal and reputational questions for NYSE:HIMS that have not been widely covered so far. For investors watching NYSE:HIMS, this legal development adds a new angle to a stock...

A confluence of safety concerns and underwhelming clinical data sent Erasca stock into a historic tailspin on Tuesday. Erasca late Monday reported positive Phase 1 trial results for ERAS-0015, a therapeutic drug candidate tailored to patients with lung and pancreatic cancer. Investors quickly drew parallels to daraxonrasib, the high-profile lead asset from Revolution Medicines Daraxonrasib has been on the receiving end of a storm of media coverage following an endorsement from former Nebraska Sen. Ben Sasse.